Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T21:28:45.884Z.
Calculation as of: 2026-10-06T21:28:45.884Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a212b8c45fb170636f79061a8993a9d466e21915543081357b5b59dac86f944c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$321.76M
EV/EBIT Ratio
34.52x
TTM Avg
44.92x
3Y Avg
44.92x
5Y Avg
44.92x
Market Cap
$309.19M
EV/EBIT Ratio
N/A
TTM Avg
23.87x
3Y Avg
23.87x
5Y Avg
23.87x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Avita Medical Inc. (RCEL) | $322.71M | N/A | N/A | N/A | N/A |
| Sanara MedTech Inc. (SMTI)vs › | $321.76M | 34.52x | 44.92x | 44.92x | 44.92x |
| CapsoVision, Inc. (CV)vs › | $324.76M | N/A | N/A | N/A | N/A |
| C4 Therapeutics, Inc. (CCCC)vs › | $318.43M | N/A | N/A | N/A | N/A |
| Cabaletta Bio, Inc. (CABA)vs › | $329.37M | N/A | N/A | N/A | N/A |
| ClearPoint Neuro, Inc. (CLPT)vs › | $330.19M | N/A | N/A | N/A | N/A |
| Agenus Inc. (AGEN)vs › | $311.90M | 9.22x | 35.72x | 35.72x | 18.31x |
| Benitec Biopharma Inc. (BNTC)vs › | $309.19M | N/A | 23.87x | 23.87x | 23.87x |
| Relmada Therapeutics, Inc. (RLMD)vs › | $344.04M | N/A | N/A | N/A | N/A |
| Turn Therapeutics Inc. (TTRX)vs › | $346.73M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute